Shots:

• NovaRock to receive $7.5M up front and is eligible to receive ~$633M as development & sales milestones along with royalties on the sales of the licensed products in the Territory
• Flame gets the exclusive rights to NBL-015 for pancreatic and gastric cancer outside of Greater China including mainland China- Hong Kong- Macau- and Taiwan & will lead the development- regulatory approval & commercialization of NBL-015
• The companies collaborated to develop the two CD137 bispecific Ab programs by using NovaRock's NovaTE technology. The products are expected to be entered into clinical development in late 2023

| Ref: PR Newswire | Image: PR Newswire